Skip to main content
Fig. 2 | BMC Medical Ethics

Fig. 2

From: The challenges of keeping clinicians unaware of their participation in a national, cluster-randomised, implementation trial

Fig. 2

Time to ethics and locality approval for the district health boards in the DesIGN trial. *The chief executive officers from two district health boards (1 and 6) gave approval on the same day the request letter was sent. One district health board had no chief executive officer response [11]. +Prior to invitation for the participation of the research, it was established the district health board was unsuitable due to technical issues, so approval for audit was not sought [12]. # Locality approval was declined, however the exact date when the locality approval was submitted was unclear [18]

Back to article page